Results 31 to 40 of about 114,922 (215)
Frontiers in Medicine, 2021 Among increasingly common drug shortages, antimicrobial drug and vaccine shortages are the most frequently reported. This could be related to the smaller size of the market, compared to statins or antidepressant drugs.
Guillaume Beraud
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Children with acute lymphoblastic leukemia (ALL) are at risk of severe outcomes from SARS‐CoV‐2 (SCV2). In the post‐pandemic context, where most children have been infected with SCV2, there are limited data on whether vaccination remains beneficial in children with ALL.
Janna R. Shapiro +11 more
wiley +1 more source
A Novel Model for Economic Recycle Quantity with Two-Level Piecewise Constant Demand and Shortages
ComputationThis paper focuses on the production systems that may produce a proportion of recyclable defective products. The developed model is called an Economic Recycle Quantity (ERQ) model with the assumption of a full recovery of defective items.
El-Awady Attia +5 more
doaj +1 more source
Employer responses to labour shortages
Economic and Social Reports, 2022 As the labour market recovers from the COVID-19 pandemic, it is imperative to assess which strategies Canadian employers plan to use over the next few months to cope with labour scarcity. This study documents the strategies that private sector businesses
René Morissette
doaj +1 more source
The Role of Hematopoietic Cell Transplantation in Ataxia‐Telangiectasia
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Ataxia‐telangiectasia (A‐T) is a DNA repair disorder characterized by neurodegeneration, immunodeficiency, and cancer predisposition. Hematopoietic cell transplantation (HCT) is an established therapy in related disorders such as Fanconi anemia (FA) and Nijmegen breakage syndrome (NBS), but its role in A‐T is unclear.
Laila Alkhouli +3 more
wiley +1 more source
Frontiers in Pharmacology, 2022 Introduction: Product life cycle refers to all phases of a product from development to active market phase and finally the phase in which products possibly exit the market. The product life cycle of medicines in short supply has not been studied in depth,
Kati Sarnola, Heini Kari, Hanna Koskinen
doaj +1 more source
Supporting Survivor‐Centered Care Through Digital Health Integration
Pediatric Blood &Cancer, EarlyView.ABSTRACT Survivors of childhood cancer face barriers to receiving guideline‐based, long‐term follow‐up care. Two digital tools, Passport for Care (PFC) and Cancer SurvivorLink (SurvivorLink), address complementary gaps by enabling tailored survivorship care plan (SCP) generation, updating, storage, and sharing.
Jordan G. Marchak +15 more
wiley +1 more source
Voices in Bioethics, 2020 Life-saving treatments represent the heart of all medical intervention. Doctors are instructed and pledge to do no harm and to help save all patients to the best of their ability, a difficult task when life-saving treatments require scarce resources ...
Sarah Messina
doaj +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Background Establishing a comprehensive apheresis medicine program in a resource‐constrained setting presents significant structural, financial, and logistical challenges. Despite the growing clinical importance of apheresis services globally, published experience from sub‐Saharan Africa remains sparse.
Folasade Adelekan‐Popoola +4 more
wiley +1 more source
Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system
FEBS Letters, EarlyView.Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley +1 more source